The Apprentice Star Levi Hague Celebrates IVF Baby News After Genetic Testing Helps Protect His Children from Inherited Cancer Risk

By
on
24 October 2026

Former The Apprentice contestant Levi Hague and his wife Rosie are expecting their second child following IVF and embryo genetic testing, sharing how fertility treatment has helped them reduce the risk of passing on a hereditary cancer-related genetic variant to their children.

For many couples, IVF is a route to parenthood when conceiving naturally proves difficult. But for others, fertility treatment offers something equally life-changing: the possibility of reducing the risk of passing on a serious inherited medical condition.

That’s the journey former The Apprentice contestant Levi Hague and his wife Rosie have been navigating.

The Doncaster businessman and former RAF gunner has announced that the couple are expecting a baby boy in March 2027, following another successful IVF treatment.

The couple, who are already parents to daughter Ruby-Rose, also conceived through IVF, chose fertility treatment because Rosie carries an inherited genetic variant associated with an increased risk of cancer.

Their story highlights an important and sometimes lesser-known use of IVF: helping families affected by hereditary genetic conditions make informed reproductive choices.

A second IVF baby on the way

Levi, 34, shared the happy news on Instagram alongside an ultrasound image, revealing that he and Rosie are expecting a son.

The couple have already chosen his name, Louie Ben Hague, and announced his expected arrival on 31 March 2027.

But behind their joyful announcement is a deeply personal story involving genetic risk, difficult decisions and the hope offered by reproductive medicine.

Levi explained that the couple had decided to pursue IVF because of concerns about passing on Rosie’s inherited cancer-related genetic variant.

He shared that five embryos were created during treatment, but only two were found not to carry the familial variant they were testing for.

Their first selected embryo resulted in the birth of daughter Ruby-Rose.

Now, following the transfer of their second selected embryo, the couple are preparing to welcome their son.

For Levi and Rosie, the news represents another milestone in a journey shaped by their desire to reduce the risk of hereditary cancer for their children.

How IVF can help families affected by inherited cancer genes

Although IVF is widely associated with fertility difficulties, it can also be used by people who are able to conceive naturally but are concerned about passing on a serious inherited condition.

One option is preimplantation genetic testing for monogenic conditions (PGT-M).

PGT-M allows fertility specialists to test embryos created through IVF for a specific genetic variant known to be present in a family.

This may help identify embryos that do not carry the particular variant being tested for, allowing patients to make informed decisions about which embryos to transfer.

PGT-M can be considered for certain inherited conditions, including some hereditary cancer predisposition syndromes.

Examples may include genetic variants associated with:

  • BRCA1 and BRCA2 hereditary breast and ovarian cancer susceptibility
  • Lynch syndrome, which increases the risk of certain cancers, particularly colorectal and endometrial cancers
  • Familial adenomatous polyposis (FAP)
  • Li-Fraumeni syndrome
  • Other serious inherited conditions where the familial disease-causing variant has been identified

Eligibility for PGT-M depends on the specific genetic condition, clinical circumstances and the laws and regulations governing treatment.

In the UK, the Human Fertilisation and Embryology Authority (HFEA) regulates the use of PGT-M for approved conditions.

What happens during IVF with PGT-M?

The process begins with genetic counselling and testing to identify the specific variant associated with the inherited condition.

If PGT-M is considered appropriate, patients undergo an IVF cycle.

Eggs are collected following ovarian stimulation and fertilised in the laboratory.

Embryos that develop to the appropriate stage may then undergo a biopsy, where a small number of cells are removed for genetic analysis.

The laboratory tests these cells for the familial genetic variant.

Embryos identified as not carrying the variant may then be considered for transfer, taking into account embryo development, test findings and clinical circumstances.

However, not every IVF cycle will produce embryos suitable for testing, and not every tested embryo will be suitable for transfer.

PGT-M is highly specialised, and testing limitations, inconclusive results and the possibility of diagnostic error should be discussed with a genetics specialist.

Prenatal diagnostic testing may also be offered to confirm results during pregnancy.

Five embryos, two without the familial variant

Levi’s account of the couple’s treatment offers an insight into the decisions families can face during IVF with genetic testing.

Of the five embryos created, he reported that two did not carry the cancer-related variant being tested for.

Those two embryos have now resulted in the couple welcoming their daughter and expecting their second child.

Their experience demonstrates how genetic testing can help some families reduce the likelihood of passing on a known inherited condition.

However, outcomes vary considerably.

The number of embryos available, the inheritance pattern of the condition, embryo development and other individual factors can all affect the chances of having an embryo suitable for transfer.

Not everyone undergoing IVF with PGT-M will have the same outcome, and some people may require more than one treatment cycle.

Can IVF eliminate hereditary cancer from a family?

In his announcement, Levi expressed his happiness that IVF had enabled the couple to avoid passing on the familial cancer-related variant to their children.

It’s an understandable sentiment and one that reflects the significance of this treatment for families living with inherited cancer risks.

However, there is an important medical distinction.

PGT-M can help reduce the risk of transmitting a specific inherited genetic variant, but it does not eliminate all cancer risks or eradicate a genetic condition from an entire family.

A child who does not inherit the tested familial variant will not pass that particular variant to their own children, but they can still develop cancer for unrelated genetic, environmental or other reasons.

Similarly, inheriting a cancer-predisposing variant does not always mean someone will develop cancer. The level of risk depends on the specific gene and variant involved.

This is why specialist genetic counselling is so important when considering reproductive options.

Why genetic counselling matters before IVF

For individuals and couples who know that a serious inherited condition runs in their family, genetic counselling can be an important first step.

A genetic counsellor or clinical genetics specialist can help explain:

  • Whether a condition is inherited and how it may be passed on
  • The likelihood of transmitting a specific genetic variant
  • What genetic testing is available
  • Whether IVF with PGT-M may be appropriate
  • The benefits, limitations and possible outcomes of testing
  • Other reproductive options, including natural conception with or without prenatal testing, donor conception and adoption

The aim is not to tell patients which reproductive decision to make, but to provide clear information and support so they can make choices that are right for their circumstances.

The emotional side of IVF and genetic testing

For families affected by hereditary conditions, reproductive decisions can carry an additional emotional burden.

There may be anxiety about a child’s future health, difficult conversations about inherited risk and uncertainty about whether treatment will produce suitable embryos.

IVF itself can be physically and emotionally demanding.

For some people, genetic testing offers reassurance and a greater sense of reproductive choice. For others, the process may raise complicated ethical, emotional or financial questions.

There is no single right path.

What matters is that individuals and couples have access to accurate information, appropriate counselling and compassionate medical care.

How IVFbabble and Babble Connect can help

At IVFbabble, we believe everyone deserves access to clear, reliable information about their reproductive health and the options available to them.

Through our fertility support platform, Babble Connect, we’re helping patients explore fertility treatment, understand genetic testing and discover clinics and specialists who may be able to support their journey.

Our educational resources cover IVF, embryo development, genetic testing, fertility preservation and other aspects of reproductive medicine.

Babble Connect also offers fertility planning tools, international clinic information and AI-supported educational guidance to help patients prepare questions for qualified specialists.

AI guidance cannot replace personalised genetic counselling, diagnosis or treatment recommendations.

If you have a family history of cancer or a known inherited genetic condition, speaking with a clinical genetics specialist can help you understand whether genetic testing or reproductive options such as PGT-M may be relevant.

A happy new chapter for Levi and Rosie

After navigating IVF and genetic testing to reduce the risk of passing on a hereditary cancer-related variant, Levi and Rosie are now looking forward to welcoming their second child.

Their story is a reminder that IVF is about much more than overcoming infertility.

For some families, it also provides an opportunity to make reproductive choices in the context of inherited health risks.

And while no treatment can guarantee a child’s future health, advances in reproductive genetics are giving some families options that previous generations did not have.

From everyone at IVFbabble, congratulations to Levi, Rosie and Ruby-Rose on their wonderful news. We wish them all the very best as they prepare to welcome baby Louie.

Sources and medical references

News source: Darren Burke, Doncaster Free Press, 21 October 2026, reporting on Levi Hague’s Instagram announcement.

UK – Human Fertilisation and Embryology Authority (HFEA)

Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

Official UK guidance explaining how IVF and PGT-M can help families reduce the risk of passing on certain serious inherited genetic conditions.

United States – American Society for Reproductive Medicine (ASRM)

Indications and Management of Preimplantation Genetic Testing for Monogenic Conditions

Clinical guidance explaining the use of PGT-M for inherited genetic conditions, including its benefits, limitations and the importance of genetic counselling.

Australia – Reproductive Technology Council, Western Australia

Preimplantation Genetic Testing

Official Australian state-level guidance explaining PGT-M, genetic testing eligibility and the approval requirements for testing embryos affected by inherited conditions.

Australia – The Royal Women’s Hospital, Melbourne

Public Fertility Care and Preimplantation Genetic Testing

Information about access to PGT-M and PGT-SR through an Australian public fertility service, including specialist referrals and genetic counselling.

Medical disclaimer: PGT-M may help reduce the risk of passing on specific inherited genetic conditions, but it cannot guarantee a healthy pregnancy or child. Eligibility, availability and regulatory requirements vary between countries and, in Australia, between states. Patients should consult a fertility specialist and qualified genetic counsellor.

Medical disclaimer: This article is intended for general information and does not replace personalised advice from a fertility specialist or clinical genetics professional.

Share this article
Leave a Reply

Latest News

Want all the best bits from IVFbabble delivered to your inbox weekly?